Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Protagenix Therapeutics is currently trading as an over-the-counter stock. But the company plans to launche on the New York Stock Exchange (NYSE) soon, which will make it easier for everyday investors to buy in.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $0.59 |
|---|---|
| 52-week range | $0.33 - $1.23 |
| 50-day moving average | $0.49 |
| 200-day moving average | $0.65 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.29 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.59 from 2023-01-27
| 1 week (2023-01-23) | 5.36% |
|---|---|
| 1 month (2022-12-30) | 47.50% |
| 3 months (2022-10-28) | 0.59 |
| 6 months (2022-07-29) | 0.59 |
| 1 year (2022-01-28) | -46.36% |
|---|---|
| 2 years (2021-01-28) | -85.78% |
| 3 years (2020-01-30) | 1.4101 |
| 5 years (2018-01-26) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.63% |
| Return on equity TTM | -43.31% |
| Profit margin | 0% |
| Book value | $0.43 |
| Market capitalisation | $9.7 million |
TTM: trailing 12 months
We're not expecting Protagenic Therapeutics to pay a dividend over the next 12 months.
Protagenic Therapeutics's shares were split on a 1:15464 basis on 27 July 2016. So if you had owned 15464 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protagenic Therapeutics shares – just the quantity. However, indirectly, the new 1546300% higher share price could have impacted the market appetite for Protagenic Therapeutics shares which in turn could have impacted Protagenic Therapeutics's share price.
Over the last 12 months, Protagenic Therapeutics's shares have ranged in value from as little as $0.33 up to $1.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagenic Therapeutics's is 0.0572. This would suggest that Protagenic Therapeutics's shares are less volatile than average (for this exchange).
To put Protagenic Therapeutics's beta into context you can compare it against those of similar companies.
Protagenic Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.